Illness	Number of cases
Malignant neoplasm of bronchus and lung (C34.1)	84
Malignant neoplasm of rectum (C20)	82
Malignant neoplasm of bronchus and lung (C34.3)	69
Malignant neoplasm without specification of site - Disseminated malignant neoplasm unspecified (C80.0)	64
Non-follicular lymphoma (C83.3)	64
Malignant neoplasm of pancreas - Malignant neoplasm of head of pancreas (C25.0)	62
Malignant neoplasm of pancreas - Malignant neoplasm of overlapping sites of pancreas (C25.8)	45
Malignant neoplasm of bronchus and lung (C34.8)	32
Malignant neoplasm of stomach - Malignant neoplasm of cardia (C16.0)	30
Malignant neoplasm of pancreas - Malignant neoplasm of tail of pancreas (C25.2)	30

Top 10 treatments

Treatment	Number
Others therapeutic procedures to influence the immune system (8-547.0)	313
Cancer treatment for several days (e.g. 2-4 days) with two or more chemotherapy drugs administered into a vein (8-543.33)	259
Cancer treatment for several days (e.g. 2-4 days) with two or more chemotherapy drugs administered into a vein (8-543.32)	203
Cancer treatment for several days (e.g. 2-4 days) with two or more chemotherapy drugs administered into a vein (8-543.22)	167
Insertion or exchange of a tube (catheter) in a large vein (8-831.0)	159
Computer-assisted analysis of the images with 3D-analysis (3-990)	141
(9-984.7)	116
Computed tomography of the abdomen with contrast medium (3-225)	94
Computed tomography of the chest with contrast medium (3-222)	93
(9-984.8)	90

Further information about the department

Out-patient accident insurance doctor approval

In-patient Employers’ Liability Insurance Association approval

Department key

Department key: 0500

Type of specialist department

Main Department

Hospital information and services for all specialist departments

Services

Quality

External comparative quality assurance

Further information

External quality assurance according to state law
No participation

Quality of participation in the Disease Management Programme (DMP)
No participation

Implementation of resolutions of the Federal Joint Committee on quality assurance (G-BA)
No participation

Further training
pursuant to Article 136b, para. 1, sentence 1, no. 1 of the SGB

Number	Group
15	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
15	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
15	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

Accessibility

Accessibility information

General information

Research & teaching

Job	Explanation
Participation in multi-centre Phase I/II studies
Editors of scientific journals/textbooks
Participation in multi-centre phase III/IV studies
Doctoral supervision
Lectureships / teaching posts at colleges and universities
Student training (clinical traineeship / internship year)
Project-related cooperation with colleges and universities